# COVID-19 Immunologic Antiviral Therapy With Omalizumab

> **NCT04720612** · PHASE2 · UNKNOWN · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 40 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Omalizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04720612
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-15
- **Primary completion:** 2022-11-07
- **Final completion:** 2022-12-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720612, "COVID-19 Immunologic Antiviral Therapy With Omalizumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04720612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*